408 / 1082
S393
ESTRO 36 2017
_______________________________________________________________________________________________
major bleeding during the course of anticoagulation in
cancer patients with or without RT.
Results
As of May 2015, 9284 patients with active cancer and VTE
were enrolled in RIETE: 4605 with pulmonary embolism
(PE) and 4679 with deep vein thrombosis (DVT). In all,
1202 (13%) were receiving RT. During the course of
anticoagulant therapy (mean: 181 days), 210 patients
presented with PE recurrences (53 fatal), 226 with DVT
recurrences and 443 with major bleeding (60 in the brain,
118 fatal). Patients receiving RT had a higher rate of PE
recurrences (risk ratio [RR]: 1.56; 95%CI: 1.08-2.21) and a
similar rate of DVT recurrences (RR: 0.80; 95%CI: 0.50-
1.22) or major bleeding (RR: 1.18; 95%CI: 0.90-1.55) than
those not receiving RT. Moreover, patients on RT had a
higher rate of cerebral bleeding (RR: 2.05; 95%CI: 1.07-
3.71). Multivariable analysis confirmed that patients
receiving radiotherapy were at an increased risk for
cerebral bleeding (hazard ratio: 2.71; 95%CI: 1.13-6.48).
Conclusion
During the course of anticoagulant therapy, cancer
patients with VTE receiving RT had a higher rate of PE
recurrence and a higher rate of cerebral bleeding than
those not receiving RT.
PO-0754 ISIORT pooled analysis 2016: characteristics
of intraoperative radiotherapy in 11,025 patients
M. Krengli
1
, F. Calvo
2
, F. Sedlmayer
3
, C. Schumacher
4
, F.
Cazzaniga
5
, M. Alessandro
6
, A. De Paoli
7
, E. Russi
8
, M.
Kruszyna
9
, R. Corvò
10
, F. Wenz
11
, R. Mazzarotto
12
, F.
Fusconi
13
, A. Ciabattoni
14
, R. Weytjens
15
, G. Ivaldi
16
, A.
Baldissera
17
, C. Pisani
1
, V. Morillo
18
, M. Osti
19
, N. Bese
20
,
G. Catalano
21
, A. Stefanelli
22
, C. Iotti
23
, L. Tomio
24
1
University of Piemonte Orientale, Radiotherapy,
Novara, Italy
2
Gregorio Maranon, Radiotherapy, Madrid, Spain
3
Paracelsus Medical University, Radiotherapy, Salzburg,
Austria
4
St. Elisabeth Hospital, Radiotherapy, Cologne, Germany
5
ASST Papa Giovanni XXIII, Radiotherapy, Bergamo, Italy
6
Ospedale USL1, Radiotherapy, Città di Castello, Italy
7
CRO, Radiotherapy, Aviano, Italy
8
Azienda Ospedaliera S. Croce e Carle, Radiotherapy,
Cuneo, Italy
9
Hospital, Radiotherapy, Poznan, Poland
10
Ospedale San Martino, Radiotherapy, Genova, Italy
11
University Hospital, Radiotherapy, Mannheim, Germany
12
University Hospital, Radiotherapy, Verona, Italy
13
Hospital, Radiotherapy, Foligno, Italy
14
San Filippo Neri Hospital, Radiotherapy, Roma, Italy
15
GasthuisZusters Antwerpen -GZA, Radiotherapy,
Wilrijk, Belgium
16
Fondazione Maugeri, Radiotherapy, Pavia, Italy
17
Bellaria Hospital, Radiotherapy, Bologna, Italy
18
Hospital General Universitario de Castellón,
Radiotherapy, Castellon, Spain
19
Sant'Andrea Hospital, Radiotherapy, Roma, Italy
20
Acibadem Maslak Hospital, Radiotherapy, Istanbul,
Turkey
21
Multimedica Hospital, Radiotherapy, Sesto San
Giovanni- Castellanza, Italy
22
Sant'Anna Hospital, Radiotherapy, Ferrara, Italy
23
Azienda Ospedaliera di Reggio Emilia, Radiotherapy,
Reggio Emilia, Italy
24
Santa Chiara Hospital, Radiotherapy, Trento, Italy
Purpose or Objective
Data from centres active in intraoperative radiotherapy
(IORT) were collected within the International Society of
Intraoperative Radiotherapy (ISIORT) program. The
purpose of the present analysis was to analyse and report
the main clinical and technical variables of IORT
performed by the participating centres.
Material and Methods
In 2007, the ISIORT-Europe centres were invited to record
demographic, clinical and technical data relating to their
IORT procedures in a joint online database.
Results
The numbers of centres increased from 3 centres in 2007
to 42 centres and 11,025 IORT procedures have been
recorded until October, 2016. 96% of treatment was
performed with electrons, while 448 treatments were
performed with x-rays. Median age of patients was 56.2
years (range: 5 months – 89 years). Gender was female in
81.2% of cases and male in 18.8%. Treatments were
curative in 10,482 cases (98.2%) and 2,545 (23.8%) cases
were included in study protocols. The most frequent
tumour was breast cancer with 8,425 cases (76.4%)
followed by rectal cancer with 913 cases (8.3%), soft tissue
and bone sarcomas with 348 cases (3.2%), prostate cancer
with 165 cases (1.5%), gastric cancer with 120 cases (1.1%)
and pancreatic cancer with 117 cases (1.1%).
22% of patients were included in study protocols. Focusing
on breast cancer: 96.5% of cases were ductal carcinoma,
99.5% treatments had curative intense and 113 cases were
re-treating with IORT.
Conclusion
Treatment chronology shows how IORT number of
recorded cases increased according with the interest in
this ISIORT project. This survey gives an overview of
worldwide use of IORT including patient selection criteria
and treatment modalities and could represent a basis to
design future clinical trials.
PO-0755 Implementation of structural patient reported
outcome registration in clinical practice
I. Nijsten - van Riesen
1
, L. Boersma
2
, M. Brouns
1
, A.
Dekker
3
, K. Smits
4
1
MAASTRO Clinic, Projectmanager Datacentre Maastro
Clinic DCM, Maastricht, The Netherlands
2
MAASTRO Clinic, Director of Patient Care, Maastricht,
The Netherlands
3
MAASTRO Clinic, Manager Research and Education,
Maastricht, The Netherlands
4
MAASTRO Clinic, Manager of Datacentre Maastro Clinic
DCM, Maastricht, The Netherlands
Purpose or Objective
Over the last years there has been an increasing focus on
registration and national audits of quality indicators, with
the assumption that insights into the quality of a certain
treatment will increase outcomes. Within our
radiotherapy (RT) institute we have set-up a structural
outcome registration, where we first focussed on
registration of toxicity, both reported by the doctor and
by the patient. The reported toxicity was stored in a data
warehouse including dashboards to evaluate toxicity on a
population level, and to identify potential targets for
improvements in the quality of care. The current study
was done to investigate how we can directly improve
individual patient care by re-directing the patient-
reported outcome measures (PROMs) to the responsible
radiation oncologist (RO).
Material and Methods